We are looking to recruit women (ages 18-40) who have problems sleeping to help with the development of an artificial intelligence-based tool that will help improve sleep among young women. The study includes two parts. Participants will be compensated $150 for completing the first part of the study and $75 for completing the second part. The first part of…
The Columbia University Department of Otolaryngology is interested in understanding altered flavor perception through the Cognitive Flavor Assessment Protocol (CFAP), a novel multisensory diagnostic and training framework that links smell and taste function to cognitive and emotional health. You can participate in this study if you are an adult between 18…
Our research team at Columbia University is trying to understand the impact of COVID-19 on smell and taste (chemosensory) dysfunction among adult patients from the Greater New York City area. Current areas of study include: 1) Investigation of smell and taste recovery patterns among patients with COVID-19; 2) Studies on how recovery of smell and taste after…
Trouble sleeping? Do you speak Spanish and identify as Hispanic or Latino/a? Dormir Mejor team is recruiting for our study testing a smartphone application that delivers cognitive behavioral treatment for insomnia (CBT-I) among Spanish-Speaking Latino/as. To participate, fill out a study interest form by following the link: https://tinyurl.com/sleepdm or…
Trouble sleeping? Do you Identify as Latino/a and speak Spanish? Dormir Mejor team is recruiting for our study that is testing a digital cognitive behavioral therapy treatment for insomnia (CBT-I) among Spanish-speaking Latinos using a phone application! You may be eligible if: identify as Latina/o, speak Spanish, are 18 years old or older, and have…
The purpose of this study is to evaluate the efficacy and safety of ION-682884 given for 24 months in patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) also known as Familial Amyloid Polyneuropathy (FAP), and determine if it can help people with mild or moderate polyneuropathy. To be in this study you must have FAP and be…
HELIOS-A is a global Phase 3 randomized, open-label study designed to evaluate the safety and efficacy of ALN-TTRSC02 in adult patients with hATTR amyloidosis experiencing neurologic symptoms brought on by the disease. The study will also evaluate any changes in quality of life experienced by study participants. ALN-TTRSC02 utilizes the mechanism of RNA…